Recently, JDRF helped fund a clinical study using stem cells that they call the biggest advancement for Type 1 Diabetes in 100 years, since the very first insulin injection treatment.

Mesenchymal stem cells have a unique ability to transform into multiple different tissues. Stem cells are master signaling cells. The stem cells are then grown and multiplied in a lab and re-injected into their body. The catch is, it takes weeks for harvested stem cells to multiply enough to be effective. Guillorys third study is pending FDA approval and involves injecting COVID-19 patients with another persons stem cells.